Replies to post #103576 on Biotech Values

[DewDiligence]

It appears that this was a high-risk action that could have been avoided. What was the reasoning for doing this particular trial (2 unapproved drugs) at this point in time?

All-oral regimens are the future of HCV therapy. The drug-drug-interaction study of IDX184+IDX320 in healthy volunteers was a prerequisite for running a combination trial in HCV patients.